美股新聞 標題聯播 · 近 24 小時 283 則 · 25 個來源 · 最新 9/20 07:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · RCEL近 30 天 4 則 · 第 1 / 1 頁
- AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
- All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
- AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases
- Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
- Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
- AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
- Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
- Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
- AVITA Medical (RCEL) Q2 2026 Earnings Call Transcript
- AVITA Medical to Host Investor Webinar Briefing
- AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
- AVITA Medical, Inc. Q2 2026 Earnings Call Summary
- Avita Medical Shares Surge After Record Second-Quarter Performance
- Avita Medical Q2 Earnings Call Highlights
- AVITA Medical Inc (AVHHL) (Q2 2026) Earnings Call Highlights: Revenue Surges 18% to $21. ...
- AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
- AVITA Medical to Announce Second Quarter 2026 Financial Results
- AVITA Medical (RCEL) Stock Sees Fair Value Lift As Analysts Back RECELL Momentum
- Avita Medical (RCEL) Upgraded to Buy: Here's Why
- Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。